Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Shanghai Junshi Biosciences has announced the European Commission’s approval of their drug toripalimab for treating two advanced cancer types, marking a significant milestone as it becomes the only first-line treatment for NPC and advanced or metastatic ESCC in Europe. The approval is backed by substantial clinical trial data showing toripalimab’s effectiveness in improving survival rates when combined with chemotherapy, and the drug will be available across the EU and additional European countries.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.